Porcine sapovirus isolates and immunogenic compositions therefrom
AssigneeIowa State University Research Foundation, Inc.
InventorsJianqiang Zhang, Liying Tian, Ethan Aljets
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to novel porcine sapoviruses (SaV) isolates, including SaV serially propagated in cell culture, all of which are useful in the preparation of immunogenic compositions and vaccines for treating and preventing disease in swine. The disclosure further provides characterization of pathogenicity and cross-protective immunity of contemporary porcine SaV isolates in weaned pigs, demonstrating that prior exposure to homologous strains provides greater protection against viral shedding than heterologous strains.
Claims23
An immunogenic composition comprising an inactivated or live attenuated porcine sapovirus (SaV), wherein the SaV comprises a polynucleotide having at least 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to SEQ ID NO:
- 1, 2, 3, 4, 21, 22, 23, or 24;
- and
- a pharmaceutically acceptable carrier.
A method for inducing an immune response against porcine sapovirus (SaV) in a swine comprising:
- administering to the swine an immunogenic composition comprising an inactivated or live attenuated porcine SaV, wherein the SaV comprises a polynucleotide having at least 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to SEQ ID NO:
- 1, 2, 3, 4, 21, 22, 23, or 24.
-19. (canceled)
A culture of cells comprising a porcine sapovirus (SaV), wherein the SaV comprises a polynucleotide having at least 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% sequence identity to SEQ ID NO:
- 1, 2, 3, 4, 21, 22, 23, or 24.
-49. (canceled)
An immunogenic composition comprising an inactivated or live attenuated porcine sapovirus (SaV) selected from IL25663/2022 or IA79982/2022, wherein the composition induces cross-protective immunity against heterologous SaV strains.
(canceled)
Dependencies are inferred from the claim text.